100 Technology Drive
Pittsburgh, PA 15219
Stemnion, Inc. is a privately held regenerative medicine company focused on the research, development and clinical use of its proprietary technology platform, derived from human placental cells. This platform provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies for which there is no satisfactory treatment. Stemnion’s proprietary technology platform is derived from a unique population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue, and therefore there are no ethical, religious, moral or political issues associated with their use.